Peer-reviewedCC BYPharmaceutics
A Mesalazine–Aloperine Co-Amorphous System for Simultaneous Dissolution Enhancement, Permeability Improvement, and Synergistic Anti-Ulcerative Colitis Activity: A Combined Pharmaceutics and Network Pharmacology Study
- 1Key Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, , Yantai 264005, China; (H.S.); (N.G.)
- 2Institute for Chemical Drug Control, National Institutes for Drug Control, No. 31, Huatuo Road, Beijing 102629, China; (S.Y.); (J.H.); (N.W.)
Related
- Simultaneous enhancement of photoluminescence and spin-polarization lifetime in a carbazole-functionalized TTM diradical
- Fracture propagation and permeability enhancement mechanisms induced by near-roof hydraulic fracturing in soft coal seams
- Simultaneous enhancement of biogas production and antibiotic resistance gene removal by sawdust biochar in anaerobic digestion of chicken manure
- Simultaneous enhancement of sweet corn yield and lodging resistance via silicon application with low-phosphorus management under dense planting in tropical China
- Functional Delivery of Nanoimmunotherapies in Pancreatic Ductal Adenocarcinoma: A Barrier-Informed Pharmaceutics Framework
BibTeX
@article{su2026mesalazinealoperine,
title = {{A Mesalazine–Aloperine Co-Amorphous System for Simultaneous Dissolution Enhancement, Permeability Improvement, and Synergistic Anti-Ulcerative Colitis Activity: A Combined Pharmaceutics and Network Pharmacology Study}},
author = {Huan Su and Ningzi Guo and Song Yuan and Junyi Huang and Ningyi Wei and Hui Xu and Yang Liu},
journal = {Pharmaceutics},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13708108},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Mesalazine–Aloperine Co-Amorphous System for Simultaneous Dissolution Enhancement, Permeability Improvement, and Synergistic Anti-Ulcerative Colitis Activity: A Combined Pharmaceutics and Network Pharmacology Study
AU - Huan Su
AU - Ningzi Guo
AU - Song Yuan
AU - Junyi Huang
AU - Ningyi Wei
AU - Hui Xu
AU - Yang Liu
PY - 2026
DA - 2026/10/01
JO - Pharmaceutics
UR - https://europepmc.org/article/PMC/PMC13708108
SN - 1999-4923
ER -